Virulence genes in herpes simplex virus type 1 corneal infection

Current Eye Research

Volumn 29, Issue 2-3, 2004, Pages 103-117

  Brandt, Curtis R ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Corneal infection; Herpes simplex virus; Keratitis; Virulence; Virulence genes

Indexed keywords

ACICLOVIR; GENE PRODUCT; VIRUS GLYCOPROTEIN; VIRUS PROTEIN;

ALPHA22 GENE; APOPTOSIS; CONFERENCE PAPER; CORNEA NEOVASCULARIZATION; DNA REPLICATION; GE GENE; GENE DELETION; GENE IDENTIFICATION; GG GENE; GI GENE; GK GENE; HERPES SIMPLEX KERATITIS; HERPES SIMPLEX VIRUS 1; HOST PARASITE INTERACTION; HUMAN; ICP0 GENE; IMMUNITY; IMMUNOCOMPETENCE; MARKER GENE; NONHUMAN; PRIORITY JOURNAL; VHS GENE; VIRUS CULTURE; VIRUS GENE; VIRUS GENOME; VIRUS ISOLATION; VIRUS REPLICATION; VIRUS VIRULENCE;

ANIMALS; GENES, VIRAL; HERPESVIRUS 1, HUMAN; HUMANS; KERATITIS, HERPETIC;

EID: 9344224620     PISSN: 02713683     EISSN: None     Source Type: Journal    
DOI: 10.1080/02713680490504533     Document Type: Conference Paper

References (143)

1. Whitley RJ. Herpes simplex viruses. In: Fields BN, Knipe DM, Howley PM, editors. Fields Virology, 3rd ed. Philadelphia: Lippincott-Raven; 1996:2297-2342.
2. Binder PS. Herpes simplex keratitis. Surv Ophthalmol. 1977;21:313-330.
3. Feenstra RP, Tseng SC. Comparison of fluorescein and rose bengal staining. Ophthalmology. 1992;99:605-617.
4. Liesegang TJ, Melton LJ, Daly PJ, Ilstrup DM. Epidemiology of ocular herpes simplex. Incidence in Rochester, Minn, 1950 through 1982. Arch Ophthalmol. 1989;107: 1155-1159.
5. Brandt CR. Susceptibility of +/+, +/nu and nu/nu BALB/c mice to ocular herpes simplex virus infection. Ophthalmic Res. 1992;24:332-337.
6. O'Brien WJ, Guy J, Taylor JL. Pathogenesis of corneal oedema associated with herpetic eye disease. Br J Ophthalmol. 1990;74:723-730.
7. Carr DJJ, Härle P, Gebhardt BM. The immune response to ocular herpes simplex virus type 1 infection. Exp Biol Med. 2001;226:353-366.
8. Lopez C. Genetics of natural resistance to herpes virus infections in mice. Nature. 1975;258:152.
9. Wu L, Morahan PS. Macrophages and other nonspecific defenses: Role in modulating resistance against herpes simplex virus. Curr Topics Microbiol Immunol. 1992;179: 89-110.
10. Metcalf JF, Michaelis BA. Herpetic keratitis in inbred mice. Invest Ophthalmol Vis Sci. 1984;25:1222-1225.
11. Doymaz MZ, Rouse BT. Immunopathology of herpes simplex virus infections. Curr Topics Microbiol Immunol. 1992;179:121-136.
12. Streilein JW, Dana MR, Ksander BR. Immunity causing blindness: Five different paths to herpes stromal keratitis. Immunol Today. 1997;18:443-449.
13. Ghiasi H, Cai S, Slanina S, Nesburn AB, Wechsler SL. Nonneutralizing antibody against the glycoprotein K of herpes simplex virus type-1 exacerbates herpes simplex virus type-1-induced corneal scarring in various virus-mouse strain combinations. Invest Ophthalmol Vis Sci. 1997;38:1213-1221.
14. Zhao Z-S, Granucci F, Yeh L, Schaffer PA, Cantor H. Molecular mimicry by herpes simplex virus-type 1: Autoimmune disease after viral infection. Science. 1998; 279:1344-1347.
15. Deshpande SP, Lee S, Zheng M, Song B, Knipe D, Kapp JA, Rouse BT. Herpes simplex virus-induced keratitis: Evaluation of the role of molecular mimicry in lesion pathogenesis. J Virol. 2001;75:3077-3088.
16. Ellison AR, Yang L, Cevallos AV, Margolis TP. Analysis of the herpes simplex virus type 1 UL6 gene in patients with stromal keratitis. Virology. 2003;310:24-28.
17. Grau DR, Visalli RJ, Brandt CR. Herpes simplex virus stromal keratitis is not titer-dependent and does not correlate with neurovirulence. Invest Ophthalmol Vis Sci. 1989;30:2474-2480.
18. Wander AH, Centifanto YM, Kaufman HE. Strain specificity of clinical isolates of herpes simplex virus. Arch Ophthalmol. 1980;98:1458-1461.
19. Williams LE, Nesburn AB, Kaufman HE. Experimental induction of disciform keratitis. Arch Ophthalmol. 1965; 73:112.
20. Roizman B, Sears AE. Herpes simplex viruses and their replication. In: Fields BN, Knipe DM, Howley PM, editors. Virology. 3rd ed. New York: Lippincott-Raven, 1996:2231-2295.
21. Post LE, Roizman B. A generalized technique for deletion of specific genes in large genomes: α gene 22 of herpes simplex virus 1 is not essential for growth. Cell. 1981; 25:227-232.
22. Field HJ, Coen DM. Pathogenicity of herpes simplex virus mutants containing drug resistance mutations in the viral DNA polymerase gene. J Virol. 1986;60:286-289.
23. Centifanto-Fitzgerald YM, Yamaguchi T, Kaufman HE, Tognon M, Roizman B. Ocular disease pattern induced by herpes simplex virus is genetically determined by a specific region of viral DNA. J Exp Med. 1982;155:475-489.
24. Thompson RL, Stevens JG. Biological characterization of a herpes simplex virus intertypic recombinant which is completely and specifically non-neurovirulent. Virology. 1983;131:171-179.
25. Subak-Sharpe JH, Timbury MC. Genetics of herpes viruses. In: Fraenkel-Conrat H, Wagner RR, editors. Comprehensive virology. New York: Academic Press, 1977:89-131.
26. Goldstein DJ, Weller SK. Herpes simplex virus Type-1 ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: Isolation and characterization of an ICP6 lacZ insertion mutant. J Virol. 1988;62: 196-205.
27. Desai P, Person S. Incorporation of the green fluorescent protein into the herpes simplex virus type 1 capsid. J Virol. 1998;72:7563-7568.
28. Elliott G, O'Hare P. Live-cell analysis of a green fluorescent protein-tagged herpes simplex virus infection. J Virol. 1999;73:4110-4119.
29. Kolb AW, Brandt CR. Enhanced isolation of low frequency herpes simplex virus recombinants using green-fluorescent protein and FACS. J Virol Methods. 2004;115:73-81.
30. Tanaka M, Kagawa H, Yamanashi Y, Sata T, Kawaguchi Y. Construction of an excisable bacterial artificial chromosome containing a full-length infectious clone of herpes simplex virus Type 1: Viruses reconstituted from the clone exhibit wild-type properties in vivo and in vitro. J Virol. 2003;77:1382-1391.
31. Roizman B, Knipe DM. Herpes simplex viruses and their replication. In: Knipe DM, Howley PM, editors. Fields Virology. 4th ed. Philadelphia: Lippincott, Williams & Wilkins; 2001:2399-2460.
32. DeLuca NA, Schaffer PA. Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4. J Virol. 1985;56:558-570.
33. Dixon RA, Schaffer PA. Fine-structure mapping and functional analysis of temperature-sensitive mutants in the gene encoding the herpes simplex virus type 1 immediate early protein VP175. J Virol. 1980;36:189-203.
34. Preston CM. Control of herpes simplex virus type 1 mRNA synthesis in cells infected with wild-type virus or the temperature-sensitive mutant tsK. J Virol. 1979;29:275-284.
35. McGregor F, Phelan A, Dunlop J, Clements JB. Regulation of herpes simplex virus poly(A) site usage and the action of immediate-early protein IE63 in the early-late switch. J Virol. 1996;70:1931-1940.
36. McLauchlan J, Phelan A, Loney C, Sandri-Goldin RM, Clements JB. Herpes simplex virus IE63 acts at the posttranscriptional level to stimulate viral mRNA 3′ processing. J Virol. 1992;66:6939-6945.
37. Hardy WR, Sandri-Goldin RM. Herpes simplex virus inhibits host cell splicing and regulatory protein ICP27 is required for this effect. J Virol. 1994;68:7790-7799.
38. Lindberg A, Kreivi JP. Splicing inhibition at the level of spliceosome assembly in the presence of herpes simplex virus protein ICP27. Virology. 2002;294:189-198.
39. Chen IH, Sciabica KS, Sandri-Goldin RM. ICP27 interacts with the RNA export factor Aly/REF to direct herpes simplex virus type 1 intronless mRNAs to the TAP export pathway. J Virol. 2002;76:12877-12889.
40. Cheung P, Ellison KS, Verity R, Smiley JR. Herpes simplex virus ICP27 induces cytoplasmic accumulation of unspliced polyadenylated alpha-globin pre-mRNA in infected cells. J Virol. 2000;74:2913-2919.
41. Koffa MD, Clements JB, Izaurralde E, Wadd S, Wilson SA, Mattaj IW, Kuersten S. Herpes simplex virus ICP27 protein provides viral mRNAs with access to the cellular mRNA export pathway. EMBO J. 2001;20:5769-5778.
42. Sandri-Goldin RM. ICP27 mediates HSV RNA export by shutting through a leucine-rich nuclear export signal and binding viral intronless RNAs through an RGG motif. Genes Dev. 1998;12:868-879.
43. Van Sant C, Kawaguchi Y, Roizman B. A single amino acid substitution in the cyclin D binding domain of the infected cell protein no. 0 abrogates the neuroinvasiveness of herpes simplex virus without affecting its ability to replicate. Proc Natl Acad Sci USA. 1999;96:8184-8189.
44. Everett RD. ICP0, a regulator of herpes simplex virus during lytic and latent infection. Bioessays. 2000;22: 761-770.
45. Ahn JH, Hayward GS. Disruption of PML-associated nuclear bodies by IE1 correlates with efficient early stages of viral gene expression and DNA replication in human cytomegalovirus infection. Virology. 2002;274:39-55.
46. Lopez P, Jacob RJ, Roizman B. Overexpression of promyelocytic leukemia protein precludes the dispersal of ND10 structures and has no effect on accumulation of infectious herpes simplex virus type 1 or its proteins. J Virol. 2002;76:9355-9367.
47. Gordon YJ, Romanowski E, Balouris C, Araullo-Cruz T. A herpes simplex type IICPO deletion mutant demonstrates diminished pathogenicity during acute ocular infection in different host animals. Invest Ophthalmol Vis Sci. 1990; 31:681-688.
48. Cai W, Astor TL, Liptak LM, Cho C, Coen DM, Schaffer PA. The herpes simplex virus type 1 regulatory protein ICP0 enhances virus replication during acute infection and reactivation from latency. J Virol. 1993;67: 7501-7512.
49. Fruh K, Ahn K, Djaballah H, Sempe P, van Endert R, Tampe R, Peterson PA, Yang Y. A viral inhibitor of peptide transporters for antigen presentation. Nature. 1995;375:415-418.
50. Hill AB, Jugovic P, York I, Russ G, Bennick J, Yewdell J, Ploegh H, Johnson D. Herpes simplex virus turns off the TAP to evade host immunity. Nature. 1995;375:411-415.
51. Lacaille VG, Androlewicz MJ. Herpes simplex virus inhibitor ICP47 destabilizes the transporter associated with antigen processing (TAP) heterodimer. J Biol Chem. 1998;273:17386-17390.
52. Jugovic P, Hill AM, Tomazin R, Ploegh H, Johnson DC. Inhibition of major histocompatibility complex class I antigen presentation in pig and primate cells by herpes simplex virus type 1 and 2 ICP47. J Virol. 1998;72: 5076-5084.
53. Tomazin R, Hill AB, Jugovic P, York I, van Endert R, Ploegh H, Andrews DW, Johnson DC. Stable binding of the herpes simplex virus ICP47 protein to the peptide binding site of TAP. EMBO J. 1996;15:3256-3266.
54. Ahn K, Meyer TH, Uebel S, Sempe P, Djaballah H, Yang Y, Peterson PA, Fruh K, Tampe R. Molecular mechanism and species specificity of TAP inhibition by herpes simplex virus ICP47. EMBO J. 1996;15:3247-3255.
55. Meignier B, Longnecker R, Mavromara-Nazos P, Sears AE, Roizman B. Virulence of and establishment of latency by genetically engineered deletion mutants of herpes simplex virus 1. Virology. 1988;162:251-254.
56. Goldsmith K, Chen W, Johnson DC, Hendricks RL. ICP47 enhances herpes simplex virus neurovirulence by blocking CD8+ T cell response. J Exp Med. 1998;187:341-348.
57. Sears AE, Halliburton IW, Meignier B, Silver S, Roizman B. Herpes simplex virus 1 mutant deleted in the α22 gene: Growth and gene expression in permissive and restrictive cells and establishment of latency in mice. J Virol. 1985; 55:338-346.
58. Poffenberger KL, Idowu AD, Fraser-Smith EB, Raichlen PE, Herman RC. A herpes simplex virus type 1 ICP22 deletion mutant is altered for virulence and latency in vivo. Arch Virol. 1994;139:111-119.
59. Mitchell C, Blaho JA, Roizman B. Casein kinase II specifically nucleotidylylates in vitro the amino acid sequence of the protein encoded by the α22 gene of herpes simplex virus 1. Proc Natl Acad Sci USA. 1994;91:11864-11868.
60. O'Toole JM, Aubert M, Kotsakis A, Blaho JA. Mutation of the protein tyrosine kinase consensus site in the herpes simplex virus 1 α22 gene alters ICP22 posttranslational modification. Virology. 2003;305:153-167.
61. Purves FC, Roizman B. The UL13 gene of herpes simplex virus 1 encodes the functions for posttranslational processing associated with phosphorylation of the regulatory protein α22. Proc Natl Acad Sci USA. 1992;89: 7310-7314.
62. Brandt CR, Kolb AW. Tyrosine 116 of the herpes simplex virus IEa22 protein is an ocular virulence determinant and potential phosphorylation site. Invest Ophthalmol Vis Sci. 2003;44:4601-4607.
63. Brandt CR, Kolb AW, Shah DD, Pumfery AM, Kintner RL, Jaehnig E, Van Compel JJ. Multiple determinants contribute to the virulence of HSV ocular and CNS infection and identification of serine 34 of the US1 gene as an ocular disease determinant. Invest Ophthalmol Vis Sci. 2003;44: 2657-2668.
64. Day SP, Lausch RN, Oakes JE. Evidence that the gene for herpes simplex virus type 1 DNA polymerase accounts for the capacity of an intertypic recombinant to spread from eye to central nervous system. Virology. 1988;163: 166-173.
65. Gordon YJ, Gilden DM, Becker Y. HSV-1 thymidine kinase promotes virulence and latency in the mouse. Invest Ophthalmol Vis Sci. 1983;24:599-602.
66. Field HJ, Wildy P. The pathogenicity of thymidine kinase-deficient mutants of herpes simplex virus in mice. J Hyg. 1978;81:267-277.
67. Brandt CR. Mixed ocular infections identify strains of herpes simplex virus for use in genetic studies. J Virol Methods. 1991;35:127-135.
68. Cameron JM, McDougall I, Marsden HS, Preston VG, Ryan DM, Subak-Sharpe JH. Ribonucleotide reductase encoded by Herpes simplex virus is a determinant of pathogenicity of the virus in mice and a valid antiviral target. J Gen Virol. 1988;69:2607-2612.
69. Idowu AD, Fraser-Smith EB, Poffenberger KL, Herman RC. Deletion of the herpes simplex virus type 1 ribonucleotide reductase gene alters virulence and latency in vivo. Antiviral Res. 1992;17:145-156.
70. Yamada Y, Kimura H, Morishima T, Daikoku T, Maeno K, Nishiyama Y. The pathogenicity of ribonucleotide reductase (RR) - null mutants of herpes simplex virus type 1 in mice. J Infect Dis. 1991;164:1091-1097.
71. Jacobson JG, Leib DA, Goldstein DJ, Bogard CL, Schaffer PA, Weller SK, Coen DM. A Herpes simplex virus ribonucleotide reductase deletion mutant is defective for acute and reactivatable latent infections of mice and for replication in mouse cells. Virology. 1989;173:276-283.
72. McGeoch DJ, Dalyrymple MA, Davison AJ, Dolan A, Frame MC, McNabb D, Perry LJ, Scott JE, Taylor P. The complete DNA sequence of the long unique region in the genome of herpes simplex virus type 1. J Gen Virol. 1988;69:1531-1574.
73. Langelier Y, Champoux L, Hamel M, Guilbaut C, Lamarche N, Gaudreau P, Massie B. The R1 subunit of herpes simplex virus ribonucleotide reductase is a good substrate for host cell protein kinases but is not itself a protein kinase. J Biol Chem. 1998;273:1435-1443.
74. Peng T, Hunter JRC, Nelson JW. The novel protein kinase of the RR1 subunit of herpes simplex virus has autophosphorylation and transphosphorylation activity that differs in its ATP requirements for HSV-1 and HSV-2. Virology. 1996;216:184-196.
75. Smith CC, Aurelian L. The large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP0) is associated with the virion tegument and has PK activity. Virology. 1997;234:235-242.
76. Spear PG. Entry of alphaherpesviruses into cells. Semin Virol. 1993;4:167-180.
77. Herold BC, WuDunn D, Soltys N, Spear PG. Glycoprotein C of herpes simplex virus type 1 plays a principal role in the adsorption of virus to cells and in infectivity. J Virol. 1991;65:1090-1098.
78. Visalli RJ, Brandt CR. Mutation of the herpes simplex virus-1 KOS UL45 gene reveals dose dependent effects on central nervous system growth. Arch Virol. 2002;147:519-532.
79. Dingwell KS, Brunetti CR, Hendricks RL, Tang Q, Tang M, Rainbow AJ, Johnson DC. Herpes simplex virus glycoproteins E and I facilitate cell-to-cell spread in vivo and across junctions of cultured cells. J Virol. 1994;68: 834-835.
80. Dingwell KS, Johnson DC. The herpes simplex virus gE-gI complex facilitates cell-to-cell spread and binds to components of cell junctions. J Virol. 1998;72:8933-8942.
81. Balan P, Davis-Poynter N, Bell S, Atkinson H, Browne H, Minson T. An analysis of the in vitro and in vivo phenotypes of mutants of herpes simplex virus type 1 lacking glycoproteins gG, gE, gI or the putative gJ. J Gen Virol. 1994;75:1245-1258.
82. Strelow LI, Leib DA. Analysis of conserved domains of UL41 of herpes simplex virus type 1 in virion host shutoff and pathogenesis. J Virol. 1996;70:5665-5667.
83. Jun PY, Strelow LI, Herman RC, Marsden HS, Eide T, Haarr L, Leib DA. The UL4 gene of herpes simplex virus type 1 is dispensable for latency, reactivation and pathogenesis in mice. J Gen Virol. 1998;79:1603-1611.
84. Smith TJ, Ackland-Berglund CE, Leib DA. Herpes simplex virus virion host shutoff (vhs) activity alters periocular disease in mice. J Virol. 2000;74:3598-3604.
85. Leib DA, Harrison TE, Laslo KM, Machalek MA, Moorman NJ, Virgin HW. Interferons regulate the phenotype of wild-type and mutant herpes simplex viruses in vivo. J Exp Med. 1999;189:663-672.
86. Chou J, Kern ER, Whitley RJ, Roizman B. Mapping of herpes simplex virus-I neurovirulence to γ1-34.5, a gene nonessential for growth in culture. Science. 1990;250: 1262-1265.
87. 134.5 deletion mutants in rodent models. J Clin Invest. 1993;2837-2843.
88. 134.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1α to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc Natl Acad Sci USA. 1997;94:843-848.
89. 134.5 protein of herpes simplex virus 1 has the structural and functional attributes of a protein phosphatase 1 regulatory subunit and is present in a high molecular weight complex with the enzyme in infected cells. J Biol Chem. 1998;273: 20737-20743.
90. 134.5 and UL41 genes of herpes simplex virus 1. J Virol. 2002;76:6974-6986.
91. Mulvey M, Poppers J, Sternberg D, Mohr I. Regulation of eIF2α phosphorylation by different functions that act during discrete phases in the herpes simplex virus type 1 life cycle. J Virol. 2003;77:10917-10928.
92. Ward SL, Scheuner D, Poppers J, Kaufman RJ, Mohr I, Leib DA. In vivo replication of an ICP34.5 second-site suppressor mutant following corneal infection correlates with in vitro regulation of eIF2 alpha phosphorylation. J Virol. 2003;77:4626-4634.
93. Al-Kobaisi MF, Rixon FJ, McDougall I, Preston VG. The herpes simplex virus UL33 gene product is required for the assembly of full capsids. Virology. 1991;180:380-388.
94. Reynolds AE, Fan Y, Baines JD. Characterization of the UL33 gene product of herpes simplex virus 1. Virology. 2000;266:310-318.
95. McNabb DS, Courtney RJ. Analysis of the UL36 open reading frame encoding the large tegument protein (ICP1/2) of herpes simplex virus type 1. J Virol. 1992;66:7581-7584.
96. McNabb DS, Courtney RJ. Characterization of the large tegument protein (ICP1/2) of herpes simplex virus type 1. Virology. 1992;190:221-232.
97. Schmilz JB, Albright AG, Kinchington PR, Jenkins FJ. The UL37 protein of herpes simplex virus type 1 is associated with the tegument of purified virions. Virology. 1995; 206:1055-1065.
98. Shelton LSG, Pensiero MN, Jenkins FJ. Identification and characterization of the herpes simplex virus type 1 protein encoded by the UL37 open reading frame. J Virol. 1990;64:6101-6109.
99. Tran RK, Lieu PT, Aguilar S, Wagner EK, Bloom DC. Altering the expression kinetics of VP5 results in altered virulence and pathogenesis of herpes simples virus type 1 in mice. J Virol. 2002;76:2199-2205.
100. Koelle DM, Reymond SN, Chen H, Kwok WW, McClurkan C, Gyaltsong T, Petersdorf EW, Rotkis W, Talley AR, Harrison DA. Tegument-specific, virus-reactive CD4 T cells localize to the cornea in herpes simplex virus interstitial keratitis in humans. J Virol. 2000;74: 10930-10938.
101. Verjans GM, Remeijer L, van Binnendijk RS, Cornelissen JG, Volker-Dieben HJ, Baarsma SG, Osterhaus AD. Identification and characterization of herpes simplex virus-specific CD4+ T cells in corneas of herpetic stromal keratitis patients. J Infect Dis. 1998;177:484-488.
102. Friedman HM, Cohen GH, Eisenberg RJ, Siedel CA, Cines DB. Glycoprotein C of herpes simplex virus 1 acts as a receptor for C3b complement component on infected cells. Nature. 1984;309:633-635.
103. Fries LF, Friedman HM, Cohen GH, Eisenberg RJ, Hammer CH, Frank MM. Glycoprotein C of herpes simplex virus 1 is an inhibitor of the complement cascade. J Immunol. 1986;137:1636-1641.
104. Harris SL, Frank I, Yee A, Cohen GH, Eisenberg RJ, Friedman HM. Glycoprotein C of herpes simplex virus type 1 prevents complement-mediated cell lysis and virus neutralization. J Infect Dis. 1990;162:331-337.
105. Lubinski JM, Wang L, Mastellos D, Sahu A, Lambris JD, Friedman HM. In vivo role of complement-interacting domains of herpes simplex virus type 1 glycoprotein gC. J Exp Med. 1999;190:1637-1646.
106. Johnson DC, Huber MT. Directed egress of animal viruses promotes cell-to-cell spread. J Virol. 2002;76:1-8.
107. Johnson DC, Webb M, Wisner TW, Brunetti C. Herpes simplex virus gE/gI sorts nascent virions to epithelial cell junctions, promoting virus spread. J Virol. 2001;75: 821-833.
108. Dubin G, Frank I, Friedman HM. Herpes simplex virus type 1 encodes two Fc receptors which have different binding characteristics for monomeric immunoglobulin G (IgG) and IgG complexes. J Virol. 1990;64:2725-2731.
109. Basu S, Dubin G, Basu M, Nguyen V, Friedman HM. Characterization of regions of herpes simplex virus type 1 glycoprotein E involved in binding the Fc domain of monomeric IgG and in forming a complex with glycoprotein I. J Immunol. 1995;154:260-267.
110. Nagashunmugam T, Lubinski JM, Wang L, Goldstein LT, Weeks BS, Sundaresan P, Kang EH, Dubin G, Friedman HM. In vivo immune evasion mediated by the herpes simplex virus type 1 immunoglobulin G Fc receptor. J Virol. 1998;72:5351-5359.
111. Saldanha CE, Lubinski JM, Martin C, Nagashunmugam T, Wang L, van Der Keyl H, Tal-Singer R, Friedman HM. Herpes simplex virus type 1 glycoprotein E domains involved in virus spread and disease. J Virol. 2000;74: 6712-6719.
112. Lubinski JM, Jiang M, Hook L, Chang Y, Sarver C, Mastellos D, Lambris JD, Cohen GH, Eisenberg RJ, Friedman HM. Herpes simplex virus type 1 evades the effects of antibody and complement in vivo. J Virol. 2002;76:9232-9241.
113. Mossman KL, Saffran HA, Smiley JR. Herpes simplex virus ICP0 mutants are hypersensitive to interferon. J Virol. 2000;74:2052-2056.
114. Balish MJ, Abrams ME, Pumfery AM, Brandt CR. Enhanced inhibition of herpes simplex virus type 1 growth in human corneal fibroblasts by combinations of interferon-α and -γ. J Infect Dis. 1992;166:1401-1403.
115. Ito M, Watanabe M, Kamiya H, Sakurai M. Herpes simplex virus Type 1 induces apoptosis in peripheral blood T lymphocytes. J Infect Dis. 1997;175:1220-1224.
116. Raftery MJ, Behrens CK, Müller A, Krammer PH, Walczak H, Schönrich G. Herpes simplex virus Type 1 infection of activated cytotoxic T cells: Induction of fratricide as a mechanism of viral immune evasion. J Exp Med. 1999;190:1103-1114.
117. Aubert M, Blaho J. The herpes simplex virus type 1 regulatory protein ICP27 is required for the prevention of apoptosis in infected human cells. J Virol. 1999;73:2803-2813.
118. Galvan V, Roizman B. Herpes simplex virus 1 induces and blocks apoptosis at multiple steps during infection and protects cells from exogenous inducers in a cell-type-dependent manner. Proc Natl Acad Sci USA. 1998;95:3931-3936.
119. Leopardi R, Roizman B. The Herpes simplex virus major regulatory protein ICP4 blocks apoptosis induced by the virus or by hyperthermia. Proc Natl Acad Sci USA. 1996;93:9583-9587.
120. Leopardi R, Ward PL, Ogle WO, Roizman B. Association of herpes simplex virus regulatory protein ICP22 with transcriptional complexes containing EAP, ICP4, RNA polymerase II, and viral DNA requires posttranslational modification by the UL13 protein kinase. J Virol. 1997;71:1133-1139.
121. Jerome KR, Fox R, Chen Z, Sears AE, Lee H, Corey L. Herpes simplex virus inhibits apoptosis through the action of two genes, Us5 and Us3. J Virol. 1999;73:8950-8957.
122. Wilson SE, Pedroza L, Beuerman R, Hill JM. Herpes simplex virus type-1 infection of corneal epithelial cells induces apoptosis of the underlying keratocytes. Exp Eye Res. 1997;64:775-779.
123. Aubert M, Rice SA, Blaho JA. Accumulation of herpes simplex virus type 1 early and leaky-late proteins correlates with apoptosis prevention in infected human HEp-2 cells. J Virol. 2001;75:1013-1030.
124. Zhou G, Galvan V, Campadelli-Fiume G, Roizman B. Glycoprotein D or J delivered in trans blocks apoptosis in SKN-SH cells induced by a herpes simplex virus 1 mutant lacking intact genes expressing both glycoproteins. J Virol. 2000;74:11782-11791.
125. Zhou G, Avitabile E, Campadelli-Fiume G, Roizman B. The domains of glycoprotein D required to block apoptosis induced by herpes simplex virus 1 are largely distinct from those involved in cell-cell fusion and binding to nectin1. J Virol. 2003;77:3759-3767.
126. Medici MA, Sciortino MT, Perri D, Amid C, Avitabile E, Ciotti M, Balestrieri E, De Smaele E, Franzoso G, Mastino A. Protection by herpes simplex virus glycoprotein D against Fas-mediated apoptosis: role of nuclear factor kappaB. J Biol Chem. 2003;278:36059-36067.
127. Jerome KR, Chen Z, Lang R, Torres MR, Hofmeister J, Smith S, Fox R, Froelich CJ, Corey L. HSV and glycoprotein J inhibit caspase activation and apoptosis induced by granzyme B or Fas. J Immunol. 2001;67:3928-3935.
128. Munger J, Roizman B. The US3 protein kinase of herpes simplex virus 1 mediates the posttranslational modification of BAD and prevents BAD-induced programmed cell death in the absence of other viral proteins. Proc Natl Acad Sci USA. 2001;98:10410-10415.
129. Hagglund R, Munger J, Poon APW, Roizman B. US3 protein kinase of herpes simplex virus 1 blocks caspase 3 activation induced by the products of US1.5 and UL13 genes and modulates expression of transduced US1.5 open reading frame in a cell type-specific manner. J Virol. 2002;76:743-754.
130. Benetti L, Munger J, Roizman B. The herpes simplex virus 1 US3 protein kinase blocks caspase-dependent double cleavage and activation of the proapoptotic protein BAD. J Virol. 2003;77:6567-6573.
131. Patel A, Hanson J, McLean TI, Olgate J, Hilton M, Miller WE, Bachenheimer SL. Herpes simplex type 1 induction of persistent NF-kappa B nuclear translocation increases the efficiency of virus replication. Virology. 1998;247: 212-222.
132. Goodkin ML, Ting AT, Blaho JA. NF-κB is required for apoptosis prevention during herpes simplex virus type 1 infection. J Virol. 2003;77:7261-7280.
133. Mori I, Goshima F, Koshizuka T, Koide N, Sugiyama T, Yoshida T, Yokochi T, Kimura Y, Nishiyama Y. The US3 protein kinase of herpes simplex virus attenuates the activation of the c-Jun N-terminal protein kinase signal transduction pathway in infected piriform cortex neurons of C57BL/6 mice. Neurosci Lett. 2003;35:201-205.
134. Taddeo B, Luo TR, Zhang W, Roizman B. Activation of NF-kappaB in cells productively infected with HSV-1 depends on activated protein kinase R and plays no apparent role in blocking apoptosis. Proc Natl Acad Sci USA. 2003;100:12408-12413.
135. Yamauchi Y, Daikoku T, Goshima F, Nishiyama Y. Herpes simplex virus UL14 protein blocks apoptosis. Microbiol Immunol. 2003;47:685-689.
136. Perng G-C, Jones C, Ciacci-Zanella J, Stone M, Henderson G, Yukht A, Slanina SM, Hofman FM, Ghiasi H, Nesburn AB, Wechsler SL. Virus-induced neuronal apoptosis blocked by the herpes simplex virus latency-associated transcript. Science. 2000;289:1651.
137. Chen X, Schmidt MC, Goins WF, Glorioso J. Two herpes simplex virus type 1 latency-active promoters differ in their contributions to latency-associated transcript expression during lytic and latent infections. J Virol. 1995;69:7899-7908.
138. Morrow JA, Rixon FJ. Analysis of sequences important for herpes simplex virus type 1 latency-associated transcript promoter activity during lytic infection of tissue culture cells. J Gen Virol. 1994;75:309-316.
139. O'Brien WJ, Tsao L-S, Taylor JL. Tissue-specific accumulation of latency-associated transcripts in herpes virus-infected rabbits. Invest Ophthalmol Vis Sci. 1998;39: 1847-1853.
140. McLean TI, Bachenheimer SL. Activation of cJUN N-terminal kinase by herpes simplex virus type 1 enhances viral replication. J Virol. 1999;73:8415-8426.
141. Advani SJ, Hagglund R, Weichselbaum RR, Roizman B. Posttranslational processing of infected cell proteins 0 and 4 of herpes simplex virus 1 is sequential and reflects the subcellular compartment in which the proteins localize. J Virol. 2001;75:7904-7912.
142. Brandt CR, Grau DR. Mixed infection with herpes simplex virus type 1 generates recombinants with increased ocular and neurovirulence. Invest Ophthalmol Vis Sci. 1990;31: 2214-2223.
143. Javier RT, Sederati F, Stevens JG. Two antivirulent recombinants and a central infection. Science. 1984;234:746-748.